Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma
Neoadjuvant DCF was effective and well-tolerated in real-world ESCC patients. Primary TRG grade 1a or pCR showed a favorable DFS/RFS, while positive ypN and GPS were independent risk factors for worse DFS/RFS.
Authors
- Mikako Tamba (ORCID: https://orcid.org/0009-0006-1380-4325)
- Shota Fukuoka (ORCID: https://orcid.org/0000-0001-9460-4486)
- Akira Ooki (ORCID: https://orcid.org/0000-0001-7618-5775)
- Jun Kanamori (ORCID: https://orcid.org/0000-0001-8113-2184)
- Yu Imamura (ORCID: https://orcid.org/0000-0002-0036-0124)
- Hiroki Osumi (ORCID: https://orcid.org/0000-0002-4742-0446)
- Koichiro Yoshino (ORCID: https://orcid.org/0000-0002-9877-9336)
- Takeru Wakatsuki (ORCID: https://orcid.org/0000-0002-1463-3859)
- Eiji Shinozaki (ORCID: https://orcid.org/0000-0002-7448-5894)
- Shohei Udagawa (ORCID: https://orcid.org/0009-0005-2225-7346)
- Akihiko Okamura (ORCID: https://orcid.org/0000-0002-3217-8888)
- Kensei Yamaguchi (ORCID: https://orcid.org/0000-0001-6887-5709)
- Mariko Ogura
- Masayuki Watanabe
- Keisho Chin
Institutions
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1186/s12885-025-14011-4
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01